Michael J Waxman1, Daniel Griffin2, Erica Sercy3, David Bar-Or4,5. 1. Medical-Surgical Intensive Care Unit and Progressive Care Unit, Research Medical Center, Kansas City, MO, USA. 2. Pulmonary and Critical Care, University of Missouri School of Medicine, Kansas City, MO, USA. 3. Trauma Research Department, Research Medical Center, Kansas City, MO, USA. 4. Trauma Research Department, Research Medical Center, Kansas City, MO, USA. davidbme49@gmail.com. 5. Injury Outcomes Network and Trauma Research LLC, 501 E. Hampden Avenue, Room 4-454, Englewood, Colorado, 80113, USA. davidbme49@gmail.com.
Abstract
BACKGROUND: Recommendations are for nearly universal venous thromboembolism (VTE) prophylaxis in critically ill hospitalized patients because of their well-recognized risks. In those intensive care units (ICUs) where patient care is more uniformly directed, it may be expected that VTE prophylaxis would more closely follow this standard over units that are less uniform, such as open-model ICUs. METHODS: This was a retrospective cohort study on all patients aged 18+ admitted to an open ICU between 6/1/2017 and 5/31/2018. Patients were excluded if they had instructions to receive comfort measures only or required therapeutic anticoagulant administration. Prophylaxis administration practices, including administration of mechanical and/or pharmacologic prophylaxis and delayed (≥48 h post-ICU admission) initiation of pharmacologic prophylaxis, were compared between patients admitted to the ICU by the trauma service versus other departments. Root causes for opting out of pharmacological prophylaxis were documented and compared between the two study groups. RESULTS: One-hundred two study participants were admitted by the trauma service, and 98 were from a non-trauma service. Mechanical (98% trauma vs. 99% non-trauma, P = 0.99) and pharmacologic (54% vs. 44%, P = 0.16) prophylaxis rates were similar between the two admission groups. The median time from ICU admission to pharmacologic prophylaxis initiation was 53 h for the trauma service and 10 h for the non-trauma services (P ≤ 0.01). In regression analyses, trauma-service admission (odds ratio (OR) = 2.88, 95% confidence interval (CI) 1.21-6.83) and increasing ICU length of stay (OR = 1.13, 95% CI 1.05-1.21) were independently associated with pharmacologic prophylaxis use. Trauma-service admission (OR = 8.30, 95% CI 2.18-31.56) and increasing hospital length of stay (OR = 1.15, 95% CI 1.03-1.28) were independently associated with delayed prophylaxis initiation. CONCLUSIONS: Overall, the receipt of VTE prophylaxis of any type was close to 100%, due to the nearly universal use of mechanical compression devices among ICU patients in this study. However, when examining pharmacologic prophylaxis specifically, the rate was considerably lower than is currently recommended: 54% among the trauma services and 44% among non-trauma services.
BACKGROUND: Recommendations are for nearly universal venous thromboembolism (VTE) prophylaxis in critically ill hospitalized patients because of their well-recognized risks. In those intensive care units (ICUs) where patient care is more uniformly directed, it may be expected that VTE prophylaxis would more closely follow this standard over units that are less uniform, such as open-model ICUs. METHODS: This was a retrospective cohort study on all patients aged 18+ admitted to an open ICU between 6/1/2017 and 5/31/2018. Patients were excluded if they had instructions to receive comfort measures only or required therapeutic anticoagulant administration. Prophylaxis administration practices, including administration of mechanical and/or pharmacologic prophylaxis and delayed (≥48 h post-ICU admission) initiation of pharmacologic prophylaxis, were compared between patients admitted to the ICU by the trauma service versus other departments. Root causes for opting out of pharmacological prophylaxis were documented and compared between the two study groups. RESULTS: One-hundred two study participants were admitted by the trauma service, and 98 were from a non-trauma service. Mechanical (98% trauma vs. 99% non-trauma, P = 0.99) and pharmacologic (54% vs. 44%, P = 0.16) prophylaxis rates were similar between the two admission groups. The median time from ICU admission to pharmacologic prophylaxis initiation was 53 h for the trauma service and 10 h for the non-trauma services (P ≤ 0.01). In regression analyses, trauma-service admission (odds ratio (OR) = 2.88, 95% confidence interval (CI) 1.21-6.83) and increasing ICU length of stay (OR = 1.13, 95% CI 1.05-1.21) were independently associated with pharmacologic prophylaxis use. Trauma-service admission (OR = 8.30, 95% CI 2.18-31.56) and increasing hospital length of stay (OR = 1.15, 95% CI 1.03-1.28) were independently associated with delayed prophylaxis initiation. CONCLUSIONS: Overall, the receipt of VTE prophylaxis of any type was close to 100%, due to the nearly universal use of mechanical compression devices among ICU patients in this study. However, when examining pharmacologic prophylaxis specifically, the rate was considerably lower than is currently recommended: 54% among the trauma services and 44% among non-trauma services.
Entities:
Keywords:
Chemoprophylaxis; Intensive care unit; Venous thromboembolism
Authors: Henry T Stelfox; Rebecca Brundin-Mather; Andrea Soo; Jeanna Parsons Leigh; Daniel J Niven; Kirsten M Fiest; Christopher James Doig; Danny J Zuege; Barry Kushner; Fiona Clement; Sharon E Straus; Deborah J Cook; Sean M Bagshaw; Khara M Sauro Journal: Intensive Care Med Date: 2019-02-01 Impact factor: 17.440
Authors: David R Anderson; Gian Paolo Morgano; Carole Bennett; Francesco Dentali; Charles W Francis; David A Garcia; Susan R Kahn; Maryam Rahman; Anita Rajasekhar; Frederick B Rogers; Maureen A Smythe; Kari A O Tikkinen; Adolph J Yates; Tejan Baldeh; Sara Balduzzi; Jan L Brożek; Itziar Etxeandia- Ikobaltzeta; Herman Johal; Ignacio Neumann; Wojtek Wiercioch; Juan José Yepes-Nuñez; Holger J Schünemann; Philipp Dahm Journal: Blood Adv Date: 2019-12-10
Authors: Nigel S Key; Alok A Khorana; Nicole M Kuderer; Kari Bohlke; Agnes Y Y Lee; Juan I Arcelus; Sandra L Wong; Edward P Balaban; Christopher R Flowers; Charles W Francis; Leigh E Gates; Ajay K Kakkar; Mark N Levine; Howard A Liebman; Margaret A Tempero; Gary H Lyman; Anna Falanga Journal: J Clin Oncol Date: 2019-08-05 Impact factor: 44.544
Authors: Ruben J Eck; Lisa Hulshof; Renske Wiersema; Chris H L Thio; Bart Hiemstra; Niels C Gritters van den Oever; Reinold O B Gans; Iwan C C van der Horst; Karina Meijer; Frederik Keus Journal: Crit Care Date: 2021-01-12 Impact factor: 9.097
Authors: Thomas L Ortel; Ignacio Neumann; Walter Ageno; Rebecca Beyth; Nathan P Clark; Adam Cuker; Barbara A Hutten; Michael R Jaff; Veena Manja; Sam Schulman; Caitlin Thurston; Suresh Vedantham; Peter Verhamme; Daniel M Witt; Ivan D Florez; Ariel Izcovich; Robby Nieuwlaat; Stephanie Ross; Holger J Schünemann; Wojtek Wiercioch; Yuan Zhang; Yuqing Zhang Journal: Blood Adv Date: 2020-10-13